Literature DB >> 27342842

NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.

Ximena L Raffo Iraolagoitia1, Raul G Spallanzani1, Nicolás I Torres1, Romina E Araya1, Andrea Ziblat1, Carolina I Domaica1, Jessica M Sierra1, Sol Y Nuñez1, Florencia Secchiari1, Thomas F Gajewski2, Norberto W Zwirner3, Mercedes B Fuertes4.   

Abstract

Despite the classical function of NK cells in the elimination of tumor and of virus-infected cells, evidence for a regulatory role for NK cells has been emerging in different models of autoimmunity, transplantation, and viral infections. However, this role has not been fully explored in the context of a growing tumor. In this article, we show that NK cells can limit spontaneous cross-priming of tumor Ag-specific CD8(+) T cells, leading to reduced memory responses. After challenge with MC57 cells transduced to express the model Ag SIY (MC57.SIY), NK cell-depleted mice exhibited a significantly higher frequency of SIY-specific CD8(+) T cells, with enhanced IFN-γ production and cytotoxic capability. Depletion of NK cells resulted in a CD8(+) T cell population skewed toward an effector memory T phenotype that was associated with enhanced recall responses and delayed tumor growth after a secondary tumor challenge with B16.SIY cells. Dendritic cells (DCs) from NK cell-depleted tumor-bearing mice exhibited a more mature phenotype. Interestingly, tumor-infiltrating and tumor-draining lymph node NK cells displayed an upregulated expression of the inhibitory molecule programmed death ligand 1 that, through interaction with programmed death-1 expressed on DCs, limited DC activation, explaining their reduced ability to induce tumor-specific CD8(+) T cell priming. Our results suggest that NK cells can, in certain contexts, have an inhibitory effect on antitumor immunity, a finding with implications for immunotherapy in the clinic.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27342842     DOI: 10.4049/jimmunol.1502291

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

1.  KIR3DL1/S1 Allotypes Contribute Differentially to the Development of Behçet Disease.

Authors:  Harry Petrushkin; Paul J Norman; Emma Lougee; Peter Parham; Graham R Wallace; Miles R Stanford; Farida Fortune
Journal:  J Immunol       Date:  2019-08-12       Impact factor: 5.422

2.  The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.

Authors:  Wenjuan Dong; Xiaojin Wu; Shoubao Ma; Yufeng Wang; Ansel P Nalin; Zheng Zhu; Jianying Zhang; Don M Benson; Kai He; Michael A Caligiuri; Jianhua Yu
Journal:  Cancer Discov       Date:  2019-07-24       Impact factor: 39.397

3.  NK cells for PD-1/PD-L1 blockade immunotherapy: pinning down the NK cell.

Authors:  Cordelia Dunai; William J Murphy
Journal:  J Clin Invest       Date:  2018-09-10       Impact factor: 14.808

4.  The Atypical Receptor CCRL2 Is Essential for Lung Cancer Immune Surveillance.

Authors:  Annalisa Del Prete; Francesca Sozio; Tiziana Schioppa; Andrea Ponzetta; William Vermi; Stefano Calza; Mattia Bugatti; Valentina Salvi; Giovanni Bernardini; Federica Benvenuti; Annunciata Vecchi; Barbara Bottazzi; Alberto Mantovani; Silvano Sozzani
Journal:  Cancer Immunol Res       Date:  2019-09-04       Impact factor: 11.151

Review 5.  Innate immune signaling and regulation in cancer immunotherapy.

Authors:  Leticia Corrales; Vyara Matson; Blake Flood; Stefani Spranger; Thomas F Gajewski
Journal:  Cell Res       Date:  2016-12-16       Impact factor: 25.617

6.  Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.

Authors:  Tineke Casneuf; Xu Steven Xu; Homer C Adams; Amy E Axel; Christopher Chiu; Imran Khan; Tahamtan Ahmadi; Xiaoyu Yan; Sagar Lonial; Torben Plesner; Henk M Lokhorst; Niels W C J van de Donk; Pamela L Clemens; A Kate Sasser
Journal:  Blood Adv       Date:  2017-10-24

7.  NITUMID: Nonnegative matrix factorization-based Immune-TUmor MIcroenvironment Deconvolution.

Authors:  Daiwei Tang; Seyoung Park; Hongyu Zhao
Journal:  Bioinformatics       Date:  2020-03-01       Impact factor: 6.937

8.  Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer.

Authors:  Damien J Zanker; Katie L Owen; Nikola Baschuk; Alex J Spurling; Belinda S Parker
Journal:  Cancer Immunol Immunother       Date:  2021-01-15       Impact factor: 6.968

Review 9.  Natural killer cells in liver diseases.

Authors:  Meijuan Zheng; Haoyu Sun; Zhigang Tian
Journal:  Front Med       Date:  2018-04-19       Impact factor: 4.592

Review 10.  Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.

Authors:  Joachim Koch; Michael Tesar
Journal:  Transfus Med Hemother       Date:  2017-09-11       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.